Table 2.

Surface and intracellular characterization of leukocytes day 12 in blood of GL-GM immunized mice and/or TMZ IP- or TMZ IC-treated mice (median values, n = 6/group)

Cell type	Treatment
	GL-GM + TMZ IP	GL-GM + TMZ IC	GL-GM	p a,b,c
CD45 count	10,124	29,124	15,552	0.0022** ,a
F4/80 count	777	2,197	1,922	0.0022** ,a
Ly6G count	674	2,205	950	0.0043** ,a 0.0022** ,b 0.0260* ,c
CD11bGr1 count	1,189	3,138	2,531	0.0022** ,a 0.0411* ,b
CD4CD3 count	4,865	7,114	9,563	0.0411* ,a 0.0260* ,b
CD8CD3 count	2,069	3,809	4,073	0.0087** ,a 0.0260* ,b
Ki67/CD8 %	5.96	12.3	9.15	0.0022** ,a
FoxP3CD25/CD4 %	9.15	6.65	5.55	0.0649 NSa 0.0411* ,b 0.0411* ,c

Statistical differences using nonparametric Mann–Whitney U test between: ^a GL-GM + TMZ IP versus GL-GM + TMZ IC; ^b GL-GM + TMZ IP versus GL-GM; ^c GL-GM + TMZ IC versus GL-GM. All p-values in bold represent significant differences between treatments